This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Three Oversold BioTechs for Tired Gamblers: StockTwits.com

Stocks in this article: IBBPCYCBIIBGILD

NEW YORK (TheStreet) -- Investing in the biotech sector this past year has been akin to playing all-in blackjack with the FDA as dealer. The right card from the drug-approval administration and the chip stack could double or triple for a small-cap biotech firm. But one disappointing Phase II or Phase III study, and investors all go bust.

After this month's major sell-off, investors now say they are tired of gambling on small-cap biotech. iShares Nasdaq Biotechnology Index ETF (IBB) is down 13% in the past 30 days.

That has cashtaggers on StockTwits.com looking to play with the weakened big boys: companies with market caps of over $2 billion with approved, revenue-producing drugs and, ideally, a pipeline of products.

$PCYC this month's biotech sell off accelerated the inevitable gap fill possibility for many stocks $BIIB $PCYC $CELG -- Sudip Banerjee (@banerjeesudip) Mar. 29 at 09:12 PM

The potential payouts might not be as big. But the risk of losing everything is much lower. Here are three tickers that have StockTwits users talking.


#1. Pharmacyclics (PCYC)

The top trending ticker on StockTwits.com at the open Monday, Pharmacyclics has $7.53 billion market cap and an approved cancer drug. Its Imbruvica medication is used to treat leukemia patients and also people suffering from a rare blood cancer known as mantle cell lymphoma. The drug inhibits enzymes needed by tumors to spread and is being tested for efficacy against other types of cancers.

Last year, Pharmacyclics posted a $117 million profit, excluding some items, on $260.2 million in sales. It trades at nearly 29 times trailing 12-month sales. Cashtaggers say that's impressive, given the number of biotech firms worth billions on the possibility that their drug will be approved and someday see real sales.

Sentiment on the stock is 88% bullish, according to StockTwits' analytics. Analysts have a generally favorable opinion of the company. The stock has eight buy recommendations, four holds and zero sell ratings, according to the Analyst Ratings Network. Morgan Stanley initiated coverage last Wednesday, with an Equal Weight rating and a $120 price target. The stock currently trades at $100. The consensus price target is $156.25, according to ARN.

$GILD back over 70, $ISIS +7% on news, carrying over to $ALNY. $MDVN moving. $REGN simple of 300. $PCYC finding footing. All good buys dip -- So Generous (@sogenerous) Mar. 31 at 10:09 AM

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs